Table 1

Patient characteristics and clinical outcomes

Patient IDAgeRaceSexStage at diagnosisPrevious therapySite of active disease at time of study enrollmentDose levelEBV-CTL response
P1507 39 T4N1M0 (IVA) CT ×2, XRT Primary, bone, LN SD × 12 mo 
P1560 53 T4N1M0 (IVA) CT ×4, XRT Primary, sinuses, temporal lobe SD × 15 mo 
P1641 14 T4N1M1 (IVC) CT ×1, XRT Primary, bone, LN PD 
P1668 17 T4N2M0 (IVA) CT ×3, XRT Bone, LN PD 
P1708 38 T4N1M0 (IVA) CT ×2* Primary, bone, LN, lung, parotid gland PD 
P1740 15 T2bN2M0 (III) CT ×4, XRT Primary CR > 24 mo 
P1790 64 T4N2M0 (IVA) CT ×2, XRT Bone, LN, lungs PD 
P1798 40 T4N1M0 (IVA) CT ×4, XRT Bone, LN, liver PD 
Patient IDAgeRaceSexStage at diagnosisPrevious therapySite of active disease at time of study enrollmentDose levelEBV-CTL response
P1507 39 T4N1M0 (IVA) CT ×2, XRT Primary, bone, LN SD × 12 mo 
P1560 53 T4N1M0 (IVA) CT ×4, XRT Primary, sinuses, temporal lobe SD × 15 mo 
P1641 14 T4N1M1 (IVC) CT ×1, XRT Primary, bone, LN PD 
P1668 17 T4N2M0 (IVA) CT ×3, XRT Bone, LN PD 
P1708 38 T4N1M0 (IVA) CT ×2* Primary, bone, LN, lung, parotid gland PD 
P1740 15 T2bN2M0 (III) CT ×4, XRT Primary CR > 24 mo 
P1790 64 T4N2M0 (IVA) CT ×2, XRT Bone, LN, lungs PD 
P1798 40 T4N1M0 (IVA) CT ×4, XRT Bone, LN, liver PD 

A indicates Asian; B, black; C, Caucasian; M, male; F, female; mo, months; CT × n, where n is the number of previous chemotherapy regimens; XRT, radiotherapy; *, refused XRT; CR, complete response; PR, progressive disease; and SD, stable disease.

or Create an Account

Close Modal
Close Modal